Menu
Search
|

Menu

Close
X

Strongbridge Biopharma plc SBBP.OQ (NASDAQ Stock Exchange Global Select Market)

5.50 USD
-0.20 (-3.51%)
As of Jul 14
chart
Previous Close 5.70
Open 5.70
Volume 66,305
3m Avg Volume 76,328
Today’s High 5.70
Today’s Low 5.43
52 Week High 9.25
52 Week Low 5.20
Shares Outstanding (mil) 39.81
Market Capitalization (mil) 244.85
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
7
FY16
0
FY15
0
EPS (USD)
FY18
-0.658
FY17
-3.142
FY16
-2.246
FY15
-2.718
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
160.13
5.73
Price to Book (MRQ)
vs sector
22.11
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
188.87
16.72
LT Debt to Equity (MRQ)
vs sector
188.87
12.39
Return on Investment (TTM)
vs sector
-101.99
14.61
Return on Equity (TTM)
vs sector
-214.59
16.34

EXECUTIVE LEADERSHIP

John Johnson
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Matthew Pauls
Chief Executive Officer, Director, Since 2014
Salary: $131,026.00
Bonus: $210,000.00
A. Davis
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Stephen Long
Chief Legal Officer, Since 2015
Salary: --
Bonus: --
Robert Lutz
Chief Business Officer, Since 2014
Salary: $65,753.00
Bonus: $25,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

900 Northbrook Dr Ste 200
TREVOSE   PA   19053-8433

Phone: +1610.2549200

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company's commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company's lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing's syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).

SPONSORED STORIES